2408839-73-4
Chemical Structure
Edecesertib
Synonym(s): GS-5718
- CAS No.: 2408839-73-4
- Formula:C22H22FN7O2
- Molecular Weight:435.45
IUPAC Name: 4-(((R)-1-cyanoethyl)amino)-6-(3-cyanopyrrolo[1,2-b]pyridazin-7-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide
InChIKey: HORBHQPSWJRDSV-ZUOKHONESA-N
SMILES: N#C[C@@H](C)NC1=C(C(NC[C@@H](F)C(C)(O)C)=O)C=NC(C2=CC=C3N2N=CC(C#N)=C3)=C1
Biological Activity: Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Edecesertib | 99.86% | Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.
- [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical
- [3]. Feng Y, et al. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer[J]. Acta Pharmaceutica Sinica B, 2024.
- [4]. Kurochkina Y, et al. POS0673 TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES[J]. 2021.
- [5]. Kalliolias GD, et al. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. Biomedicines. 2024 Jan 9;12(1):138. [Content Brief]
Keywords
